Abeona Therapeutics Inc (ABEO.OQ)
ABEO.OQ on NASDAQ Stock Exchange Capital Market
10.09USD
3:57pm BST
10.09USD
3:57pm BST
Change (% chg)
$-0.36 (-3.44%)
$-0.36 (-3.44%)
Prev Close
$10.45
$10.45
Open
$10.41
$10.41
Day's High
$10.41
$10.41
Day's Low
$10.02
$10.02
Volume
28,039
28,039
Avg. Vol
181,692
181,692
52-wk High
$22.00
$22.00
52-wk Low
$9.68
$9.68
About
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)
Overall
| Beta: | 2.29 |
| Market Cap(Mil.): | $713.08 |
| Shares Outstanding(Mil.): | 40.29 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ABEO.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.92 | 33.73 |
| EPS (TTM): | -0.60 | -- | -- |
| ROI: | -29.33 | 0.63 | 14.31 |
| ROE: | -30.75 | 1.68 | 16.04 |
BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA
BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease
* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $201.54 | -0.80 |
| Curagen Corp (CRGN.OQ) | -- | -- |
| OSI Pharmaceuticals, Inc. (OSIP.OQ) | -- | -- |
| Bristol-Myers Squibb Co (BMY.N) | $58.83 | +1.00 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,050.20 | -- |
| Sanofi SA (SASY.PA) | €77.21 | +0.80 |
| Agenus Inc (AGEN.OQ) | $1.95 | -0.04 |
| Poniard Pharmaceuticals, Inc. (PARD.PK) | $0.05 | -- |
| NanoCarrier Co., Ltd. (4571.T) | ¥487 | +7.00 |
| Enzon Pharmaceuticals Inc (ENZN.PK) | $0.24 | -- |
Estimates